期刊文献+

联合应用尼洛替尼和汉防己甲素逆转K562/A02细胞耐药与诱导凋亡的研究 被引量:4

Inducing Apoptosis and Reversal Effect of Nilotinib in Combination with Tetrandrine on Multidrug Resistance of K562/A02 Cell Line
下载PDF
导出
摘要 本研究旨在探讨联合应用尼洛替尼(nilotinib)和汉防己甲素(tetrandrine,Tet)逆转K562/A02细胞耐药与诱导凋亡的相关性及其机制。应用MTT法检测细胞敏感性,计算尼洛替尼和Tet干预后的柔红霉素(DNR)的半数抑制浓度(IC50),用流式细胞术(FCM)检测细胞凋亡率,RT-PCR检测bax、survivin mRNA的表达及Western blot分析BAX、SURVIVIN蛋白的表达情况。结果表明:5 nmol/L尼洛替尼或1.0μml/L Tet单独作用48小时后,DNR对K562/A02细胞的IC50分别为(5.71±0.72)mg/L和(6.52±0.43)mg/L,两药联合应用时DNR对K562/A02细胞的IC50降为(3.12±0.13)mg/L。单用尼洛替尼或Tet均能增加经DNR作用的K562/A02细胞的凋亡率,两药联合作用时凋亡率增高更明显。单用5 nmol/L尼洛替尼或1.0μml/L Tet 48小时后可上调bax mRNA及其蛋白的表达,且两药联合作用时上调幅度明显。单用5 nmol/L尼洛替尼或1.0μml/LTet48小时后可下调survivin mRNA及其蛋白表达水平,且两药联合作用时下调幅度明显。结论:K562/A02细胞对DNR耐药,单独应用尼洛替尼和Tet均可部分逆转K562/A02细胞对DNR的耐药,并可增加K562/A02细胞的凋亡率,两药联用具有明显的协同作用,其机制可能与上调bax mRNA及其蛋白的表达和下调survivin mRNA及其蛋白的表达有关。 This study was aimed to investigate the relevance of nilotinib in combination with tetrandrine(Tet) on reversing multidrug resistance and inducing apoptosis of K562/A02 cell line and its mechanism.Methyl-thiazol tetrazolium(MTT) assay was employed to examine the pharmacological effect of nilotinib or Tet alone on K562/A02 cell line,the IC50 of daunorubicin(DNR) on K562/A02 cell line treated with nilotinib and Tet was calculated;the flow cytometry(FCM) was employed to detect the apoptosis rate of K562/A02.The expression of bax/survivin mRNA was determined by RT-PCR,and the expression of bax/survivin protein was assayed by Western blot.The results showed that after being treated by 5 nmol/L nilotinib or 1.0 μml/L Tet for 48 hours,IC50 of DNR to K562/A02 was 5.71±0.72 mg/L or 6.52±0.43 mg/L,respectively,while in their combined treatment,IC50 decreased to 3.12±0.13 mg/L.Nilotinib or Tet alone could increase DNR-inducing apoptosis rate of K562/A02 cell,while the apoptosis rate of K562/A02 increased remarkably in combination treatment of nilotinib with Tet.After being treated with 5 nmol/L nilotinib or 1.0 μml/L Tet alone for 48 hours,the expressions of bax mRNA and BAX protein was up-regulated,while both effects were more obvious in combination treatment of nilotinib with Tet.Treatment with 5 nmol/L nilotinib or 1.0 μmol/L Tet alone for 48 hours down-regulated the expression of survivin mRNA and its protein,while treatment of nilotinib in combination with Tet had more significant effect on down-regulation of their expression.It is concluded that the K562/A02 cells are resistant to DNR,nilotinib or Tet alone both can partially reverse resistance of K562/A02 cells to DNR,increase the apoptosis rate of K562/A02 cells.Combination of nilotinib with Tet shows obvious synergistic action,mechanism of which may associate with up-regulation of bax mRNA and BAX protein expressions and down-regulation of survivin mRNA and its protein expressions.
出处 《中国实验血液学杂志》 CAS CSCD 2011年第1期28-33,共6页 Journal of Experimental Hematology
基金 国家自然基金(编号30872970) 高等学校博士学科点专项科研基金资助(编号20070286042)
关键词 尼洛替尼 汉防己甲素 K562/A02细胞 survivin 耐药逆转 nilotinib tetrandrine K562/A02 cell bax surviving drug resistant reverse
  • 相关文献

参考文献12

二级参考文献26

共引文献97

同被引文献35

  • 1齐静,彭晖,顾振纶,梁中琴,杨纯正.伊马替尼耐药的K562细胞系的建立及其生物学特性研究[J].中华血液学杂志,2004,25(6):337-341. 被引量:20
  • 2栾凤君,杨纯正.一株人红白血病多药耐药细胞系(K562/A02)的建立及其耐药特性...[J].中华肿瘤杂志,1993,15(2):101-103. 被引量:68
  • 3邓雨霞,孙新臣.粉防己碱对人鼻咽癌细胞株CNE增殖抑制和凋亡作用的研究[J].医学研究生学报,2007,20(4):360-365. 被引量:17
  • 4DiNorcia J, Moroziewicz DN, Ippagunta N, et al. RAGE signaling sig- nificantly impacts tumorigenesis and hepatic tumor growth in routine models of colorectal carcinoma. J Gastrointest Surg, 2010; 14 ( 11 ) : 1680 - 1690.
  • 5Kang R,Tang D,Schapiro NE,et al. The receptor for advanced gly- cation end products (RAGE) sustains autophagy and limits apopto- sis, promoting pancreatic tumor cell survival. Cell Death Differ, 2010;17(4) :666 -676.
  • 6Abe R, Shimizu T, Sugawara H, et al. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermato1,2004 ; 122 ( 2 ) :461 - 467.
  • 7Zhang FL,Gao HQ,Shen L. Inhibition effect of GSPE on RAGE ex- pression induced by advanced glycation end products in endothelial cells. J Cardiovasc Pharmacol, 2007 ; 50 ( 4 ) :434 - 440.
  • 8Huebschmann AG, Regensteiner JG, Vlassara H, et al. Diabetes and advanced glycoxidation end products. Diabetes Care, 2006 ; 29 ( 6 ) : 1420 - 1432.
  • 9Sehmidt AM, Vianna M, Gerlach M, et al. Isolation and characteriza- tion of binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992:267 (21) : 14987 - 14997.
  • 10lwamoto K, Kanno K, Hyogo H, et al. Advanced glycation end prod- ucts enhance the proliferation and activation of hepatic stellate cells. J Gastroentero1,2008 ;43 (4) :298 - 304.

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部